| Date | Title | | | 12/13/17 | ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development| SAN DIEGO--(BUSINESS WIRE)--Dec. 13, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that Damien McDevitt, Ph.D., has joined
ACADIA as Senior Vice President, Corporate Development, leading the
company’s corporate development activities. He will report to Steve
... |
|  | | 11/21/17 | ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017| SAN DIEGO--(BUSINESS WIRE)--Nov. 21, 2017--
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the 29th Annual Piper
Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00
a.m. Eastern Time in New York City.
A live webcast o... |
| | | 11/07/17 | ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results| – Third Quarter Net Sales Grew to $35.6 Million
– Company Raises Annual 2017 Net Sales Guidance to Between $124
Million and $127 Million
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced its unaudited financial ... |
| | | 11/03/17 | ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting| Data Confirmed Significant Improvement in Psychosis in Patients
with Alzheimer’s Disease with Substantively Greater Benefit in Patients
with More Severe Psychotic Symptoms
SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announc... |
| | | 10/31/17 | ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017| ACADIA to Host Conference Call and Webcast on Tuesday, November 7,
2017, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the third
quarter ended Sep... |
| | | 10/04/17 | ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis| Dementia-Related Psychosis Includes Psychosis in Patients with
Alzheimer’s Disease, Dementia with Lewy Bodies, Parkinson’s Disease
Dementia, Vascular Dementia, and Frontotemporal Dementia
FDA Grants Breakthrough Therapy Designation to Pimavanserin for
Dementia-Related Psychosis
Conference Call to Be Held Today at 5:00 pm ET to Discuss Phase III
Development Program
SAN DIEGO--(BUSINESS... |
| | | 09/19/17 | ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017| SAN DIEGO--(BUSINESS WIRE)--Sep. 19, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Ladenburg Thalmann 2017
Healthcare Conference on Tuesday, September 26, 2017, at 10:00 a.m.
Eastern Time in New York City.
A live webcast of... |
| | | 08/08/17 | ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results| Second Quarter Net Sales Grew to $30.5 Million Including $3.6 Million
From Transition to Sell-In Method of Accounting
SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced its unaudited financial results for the
sec... |
| | | 08/01/17 | ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017| ACADIA to Host Conference Call and Webcast on Tuesday, August 8,
2017, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the second
quarter end... |
| | | 07/25/17 | ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies| SAN DIEGO--(BUSINESS WIRE)--Jul. 25, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has
been ranked 11th on Forbes Magazine’s 2017 list of the
World’s Most Innovative Growth Companies. ACADIA is a biopharmaceutical
company dedicated to developing and delivering innovative medicines to
address unmet medical needs in central nervous system (CNS) disorders.
“We are pleased to be recognized by Forbes as a leader in
i... |
| | | 05/09/17 | ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May 9, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced its unaudited financial results for the first
quarter ended March 31, 2017.
“We’re very pleased with our strong start to 2017,” said Steve Davis,
ACADIA’s President a... |
| | | 05/08/17 | ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017| SAN DIEGO--(BUSINESS WIRE)--May 8, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Bank of America Merrill
Lynch 2017 Healthcare Conference on Tuesday, May 16, 2017, at 10:00 a.m.
Pacific Time in Las Vegas.
A live webcast of ... |
| | | 05/02/17 | ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017| ACADIA to Host Conference Call and Webcast on Tuesday, May 9, 2017,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May 2, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the first
quarter ended March 31, ... |
| | | 03/30/17 | ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer| Terrence O. Moore Retires as Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Mar. 30, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced Michael J. Yang has joined ACADIA as
Executive Vice President and Chief Commercial Officer. Mr. Yang succeeds
Terr... |
| | | 03/29/17 | ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017| SAN DIEGO--(BUSINESS WIRE)--Mar. 29, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at Needham & Company’s 16th
Annual Healthcare Conference on Wednesday, April 5, 2017, at 10:40 a.m.
Eastern Time in New York City.
A live webca... |
| | | 02/28/17 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016| NUPLAZID® Net Product Sales Grew to $12.0
Million in Fourth Quarter 2016
Executing on Broad Clinical Development Program in Alzheimer’s
Disease Psychosis, Alzheimer’s Disease Agitation, Schizophrenia
Inadequate Response, Negative Symptoms of Schizophrenia, and Major
Depressive Disorder
SAN DIEGO--(BUSINESS WIRE)--Feb. 28, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development an... |
| | | 02/27/17 | ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017| SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Cowen and Company 37th
Annual Health Care Conference on Monday, March 6, 2017, at 1:20 p.m.
Eastern Time in Boston.
A live webcast of ACADIA... |
| | | 02/21/17 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017| ACADIA to Host Conference Call and Webcast on Tuesday, February 28,
2017, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 21, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the fourth
quarter and yea... |
| | | 01/03/17 | ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017| SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2017--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the 35th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 10, 2017, at 1:30 pm
Pacific Time in San Francisco.
A live webcast of ACADI... |
| |
|
